Viveras pharmaceuticals has come a long way since the days of its founders.
With more than 3,500 employees, Viveros products are used by nearly 20 million people worldwide, including more than 2 million in the U.S. Viverans pharmaceuticals are approved for use by the Food and Drug Administration and the Drug Enforcement Administration, and it was acquired by the United States pharmaceutical giant Pfizer in 2011.
However, with the company now valued at more than $500 million, Vivers biggest assets have been its research and development facilities, which are used to develop drugs that make up the company’s portfolio of products.
“We are a large pharmaceutical company,” said John D. Tipton, chairman of Viveran, a company that produces vaccines and other therapies for cancer and arthritis, among other diseases.
The company is known for its innovative product development programs, such as its cancer drug LPS-17, which has been approved for both humans and animals.
But Vivero’s other major assets are the company s laboratories, which make and test drugs.
“Our labs are very large, so they can handle some of the work that goes on,” Tiptons co-founder and CEO Michael Peltier told The Huffington Posts.
“But the majority of our work is done in our own labs.”
Tiptson said the company also has been working on its vaccines, which include its experimental cancer drug, VES-17.
Tipton said Vivers vaccines are designed to target different types of cancers, such a breast and ovarian cancer, as well as other diseases, including those related to inflammation and autoimmune disease.
Peltier said the Viveron team, including its researchers and scientists, are working on several vaccines that have been approved by the FDA and the DEA.
Viverans vaccines have also been approved in Europe, Japan and China.
According to the company, it is the largest pharma company in the world and one of the largest pharmaceutical companies in the United Kingdom, where it has an approximately 70% share of the market.
It was founded in 1988 by two men who have been in the pharmaceutical industry for over 20 years, Tiptont said.
Despite the companys success in the field of cancer vaccines, the two founders were also involved in the drug development for their other companies.
One of the companies, VPS Pharmaceuticals, developed VES, which was used in the VES vaccine and the VPS Cancer Vaccine, which is still on the market today.
With Viveranais revenue and profits rising year by year, Tippetts hope that Viverus pharmaceuticals will be able to make its profits.
But that is not likely to happen anytime soon.
In 2015, Tipson said, the company decided to sell its entire product portfolio, which included vaccines, to Pfizer.
While the Pfizer acquisition was expected to be a boon to Viveri s revenue, the merger would also result in a loss of approximately $6 million.
The loss was offset by an additional $1 million from the company in a merger-related stock split.
As a result, the combined company is now valued with Pfizer at approximately $8.6 billion, according to Forbes.
Read more: Pharma giant Pfizers acquisition of Vivers pharmaceuticals could make it more profitable, experts say, The acquisition will give Pfizer an opportunity to further expand its drug portfolio.
“We expect Pfizer to be able capitalize on its synergies with Vivers and the acquisition of our portfolio of VESs vaccines, and the potential synergies Pfizer could have with Vivena will enable it to capitalize on the growth in our global pharmaceuticals business,” Tippons cofounders said in a statement.
“However, the transaction will also allow Pfizer the opportunity to continue its growth in the global pharmaceutical sector, and to build on the success of Vivenas vaccine.”
Read more from The Hill: Pfizer buys up stakes in Viveranos pharmaceuticals for $2.6B (Updated)